Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.

@article{Kerr1990HeteroconjugateAK,
  title={Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.},
  author={Lindsey A Kerr and Catherine J. Huntoon and John Donohue and Paul J. Leibson and Neil Harrison Bander and Tarun I. Ghose and Stephen J Luner and R Vessella and David J. McKean},
  journal={Journal of immunology},
  year={1990},
  volume={144 10},
  pages={4060-7}
}
Tumor cell lysis can be enhanced significantly in vitro when heteroconjugate (HC) antibodies (anti-CD3 x anti-tumor mAb) are used to specifically direct lymphocyte effector cells to the tumor cell target. In order to effectively utilize HC antibodies in an immunotherapy protocol, methods must be identified for the optimum expansion, activation, and retargeting of lymphocyte-effector populations from cancer patients. In this study, we have compared the proliferative responses of different normal… CONTINUE READING